Application of everolimus increased the PFS to 10.6 months compared to 4.1 months originally with single exemestane administration (P < 0.0001) [244], which directly led to the permission of FDA for everolimus with exemestane in advanced breast cancer patients with HR positive and HER2 negative following unsuccessful therapy with letrozole or anastrozole. The gene discussed is ERBB2; the disease is breast carcinoma.